Modafinil in treatment of fatigue in multiple sclerosis, Results of an open-label study.
Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM.
Arbeitskreis fur klinische Forschung in der Neurorehabilitation Kurhausstr. 100 2222 Bad Pirawarth, Austria.
J Neurol 2002 Jul;249(8):983-7
Abstract
Background Modafinil is a unique wake-promoting agent that is chemically distinct from traditional stimulants. Results of a placebo-controlled study showed it to improve fatigue in multiple sclerosis (MS) at a dose of 200 mg daily, but not at a dose of 400 mg daily. Objective To establish the efficacy, safety and appropriate dose of modafinil in the treatment of fatigue and sleepiness in patients with multiple sclerosis. Method A total of 50 patients diagnosed with MS (mean age 40.4 10.3 years, 30 females/20 males; MS type: 36 relapsing remitting, 1 primary progressive, 13 secondary progressive; mean disability level 3.8 1.5 on the Kurtzke EDSS) and complaining of chronic fatigue were enrolled in a prospective 3-month, two-center, open-label study. Efficacy was evaluated with the Fatigue Severity Scale (FSS, score range 0-42), the Epworth Sleepiness Scale (ESS, score range 0-24) and by subjective patient appraisal of change of fatigue, quality of life and overall satisfaction with treatment. Adverse effects (AEs) were recorded throughout the study. Treatment was started with a single daily dose of 100 mg in all patients. In non-responders the dose was increased by 100 mg increments up to a maximum daily dose of 400 mg. Results Three patients discontinued modafinil because of AEs (nervousness, dizziness). Two patients (4 %) were treated with 50 mg, 25 (50 %) with 100 mg, 21 (42 %) with 200 mg and 2 (4 %) with 300 mg daily. No patient required 400 mg daily. Mean FSS scores were 30.3 8.5 at baseline and 25.4 3.7 at 3 months (p < 0.0001). Mean ESS scores were 9.7 3.9 at baseline and 4.9 2.9 at 3 months (p < 0.0001). Self-appraisal of change of fatigue showed clear improvement in 41 patients (87.2 %), some improvement in 4 (8.5 %) and no change in 2 (4.3 %). Overall clinical condition was clearly improved in 43 patients (91.5 %), somewhat improved in 1 patient (2.1 %), and unchanged in 3 patients (6.4 %). No patient reported worsening of overall clinical condition. Conclusions Treatment with modafinil significantly improves fatigue and sleepiness and is well tolerated by patients with MS. Unlike the higher dose regimen required in narcolepsy, a low-dose regimen of modafinil is effective in MS.
|
Home | to
Order |
1. Modafinil augmentation
of antidepressant treatment
2. Modafinil children
with attention-deficit/hyperactivity disorder
3. Modafinil in
fibromyalgia treatment
4. Modafinil
efficacy in narcolepsy
5. Modafinil narcolepsy:
symptoms and management
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil
drug of choice for narcolepsy
8. Modafinil
in the treatment of
narcolepsy
9. Modafinil
effect on narcolepsy
10. Modafinil
a narcolepsy study
11. Modafinil
switching from narcolepsy drugs to modafinil
12. Modafinil
and naps as counter measures in sleep deprivation
13. Modafinil
as a treatment for excessive daytime sleepiness
14. Modafinil
use in a sleep deprivation experiment
15. Modafinil excessive sleepiness in Parkinson's disease
16. Modafinil the
unique properties of a new stimulant
17. Modafinil for
sustaining the alertness of helicopter pilots
18. Modafinil dosage
and safety
19. Modafinil
treatment of alcoholic organic brain syndrome
20. Modafinil
effect on melatonin, cortisol, and growth hormone
21. Modafinil
in obstructive sleep apnea-hypopnea syndrome
22. Modafinil
vs dextroamphetamine in treatment of adult ADHD
23. Modafinil
dopaminergic transmission mediates CNS stimulants
24. Modafinil
for daytime sleepiness in sleep apnea
25. Modafinil
treatment of residual excessive daytime sleepiness
26. Modafinil
amplification of cortical serotonin release
27. Modafinil for the treatment of
multiple sclerosis
